Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 7;12(5):315–319. doi: 10.1002/(SICI)1098-2825(1998)12:5<315::AID-JCLA12>3.0.CO;2-Y

Development of an assay for modulating anti‐acetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line

Bradley W Lyons 1, Lily L Wu 1, Mark E Astill 1, James T Wu 1,✉
PMCID: PMC6807847  PMID: 9773965

Abstract

Three types of autoantibodies against the acetylcholine receptors (AchR) of skeletal muscle are detectable in patients with myasthenia gravis including binding, blocking, and modulating anti‐AChR antibodies. Modulating autoantibodies correlate best with the severity of the disease, but are also technically most difficult to measure because the assay generally requires fresh human muscle cells. We have developed an assay for the modulation of anti‐AChR antibodies using a rhabdomyosarcoma (RD) cell line expressing AchR on the cell surface. By decreasing the FetalClone III serum from 10% to 0.5% in Eagles Minimal Essential Medium (EMEM) we were able to increase the number of AchR on RD cells to meet the need of sensitivity of the assay. The extent of modulation was determined as the percent of AchR internalized in the presence or absence of modulating autoantibodies. Less than 6% modulation was found with the normal serum (n = 42). The CVs of both the intra‐ and day‐to‐day precision were less than 20%. When clinical samples (n = 105) were assayed in our laboratory and also at Nichols Institute, a correlation coefficient of 0.816 was obtained. The selection of RD cell line, the success of increasing the expression of the AchR on RD cells and the use of 125I α‐bungarotoxin of high specific activity allowed the establishment of an assay which can be used in routine clinical laboratory for the measurement of modulating anti‐AChR autoantibodies for the management of patients with myasthenia gravis. J. Clin. Lab. Anal. 12:315–319, 1998. © 1998 Wiley‐Liss, Inc.

Keywords: myasthenia gravis, bungarotoxin, endocytosis, acetylcholine receptor

References

  • 1. Howard FM Jr., Lennon VA, Finley J, Matsumoto J, Elveback LR: Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 505: 526–538, 1987. [DOI] [PubMed] [Google Scholar]
  • 2. Drachman DB, Silva SD, Ramsay D, Pestronk A: Humoral pathogenesis of myasthenia gravis. Ann N Y Acad Sci 505: 90–105, 1987. [DOI] [PubMed] [Google Scholar]
  • 3. Txartos SJ, Seybold ME, Lindstrom JM: Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 79: 188–92, 1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Stevens CF: Synaptic actions of acetylcholine: problems for future research. Fed Proceed 37: 2651–2653, 1978. [PubMed] [Google Scholar]
  • 5. Drachman DB, Adams RN, Josifek LF, Self SG: Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 307: 769–775, 1982. [DOI] [PubMed] [Google Scholar]
  • 6. McCallister RM, Melnyk J, Findlestein JZ, Adams EC, Gardner MB: Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer (1969) 24: 520–526, 1989. [DOI] [PubMed] [Google Scholar]
  • 7. Pachner AR. Anti‐acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells. Neurology 39: 1057–1061. [DOI] [PubMed] [Google Scholar]
  • 8. Luther MA, Schoepfer R, Whiting P, et al.: A muscle acetylcholine receptor is expressed in the human cerebella medulloblastoma cell line TE671. J Neuroscience 9: 1082–1096, 1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Conroy WG, Saedi MS, Lindstrom J: TE671 cells express an abundance of a partially mature acetylcholine receptor a subunit which has characteristics of an assembly intermediate. J Biol Chem 265: 21642–21651, 1990. [PubMed] [Google Scholar]
  • 10. Schoepfer R, Luther M, Lindstrom J: The human medulloblastoma cell line TE671 expresses a muscle‐like acetylcholine receptor: Cloning of the a‐subunit cDNA. FEBS Lett 226: 235–240, 1988. [DOI] [PubMed] [Google Scholar]
  • 11. Sine SM: Functional properties of human skeletal muscle acetylcholine receptors expressed by the TE671 cell line. J Biol Chem 263: 18052–18062, 1988. [PubMed] [Google Scholar]
  • 12. Stratton MR, Reeves BR, Cooper CS: Misidentified cell. Nature 337: 311–312, 1989, (scientific correspondence). [DOI] [PubMed] [Google Scholar]
  • 13. Chen TR, Dorotinsky C, Macy M, Hay R: Cell identity resolved. Nature 340: 106, 1989, (scientific correspondence). [DOI] [PubMed] [Google Scholar]
  • 14. Wu, JT : Rhabdomyosarcoma cell line expresses human acetylcholine receptor. 96th Meeting of the Association of Clinical Scientists, 1991. (abstract).
  • 15. Wu JT, Miya TG, Knight JA, Bringhurst C: Acetylcholine receptors from normal human muscle: Concentration, purification, and use in radioreceptor assays for autoantibodies. J Clin Lab Anal 5: 79–85, 1991. [DOI] [PubMed] [Google Scholar]
  • 16. Kaplan I, Blakely BT, Pavlath GK, Travis M, Blau HM: Steroids induce acetylcholine receptors on cultured human muscle: Implications for myasthenia gravis. Proc Natl Acad Sci USA 87: 8100–8104, 1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES